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Background: The role of microparticles (MPs) in the inﬂammatory process of cystic ﬁbrosis (CF) airways is not known. Here, we have studied the
pro-inﬂammatory potential of CF MPs in a model of acute lung injury.
Methods: Swiss mice were subjected to intratracheal administration of MPs obtained from CF and primary ciliary diskinesia (PCD) patients.
Histopathology, total and differential cell counts in bronchoalveolar lavage ﬂuid were used to evaluate the inﬂammatory reaction in the lung.
Lipopolysaccharide (LPS)-like activity of MPs was studied by Limulus amebocyte lysate assay.
Results: MPs obtained from acute CF patients determined peribronchial and perivascular inﬂammatory inﬁltrates similar to those elicited by LPS.
This inﬂammation was granulocyte-dominated and higher than that determined by MPs obtained from stable CF, whereas PCD MPs caused a
macrophage-dominated inﬂammation. While LPS-activity was not found in circulating blood MPs prepared from CF patients, it was present in
MPs obtained from CF sputum and sputum CD66b+ neutrophils. Finally, LPS-like activity was only detected in circulating MPs after incubation
with LPS as well as in MPs obtained from LPS-stimulated neutrophils obtained from healthy donors.
Conclusions: These data suggest that the pro-inﬂammatory potential of neutrophil-derived MPs in the CF airways may be subsequent to the
binding of shedded LPS.
© 2013 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic ﬁbrosis; Lipopolysaccharide; Lung inﬂammation; Neutrophils; Macrophages; Primary ciliary dyskinesia1. Introduction
The hallmarks of the lung disease in cystic fibrosis (CF)
patients are a persistent infection with opportunistic bacterial
pathogens and an abnormal inflammatory response dominated
by polymorphonuclear neutrophils (PMNs) and dysfunction in⁎ Corresponding author. Tel.: +39 0881 588039; fax: +39 0881 588047.
E-mail address: m.conese@unifg.it (M. Conese).
1569-1993/$ -see front matter © 2013 European Cystic Fibrosis Society. Pub
http://dx.doi.org/10.1016/j.jcf.2013.03.002lishedboth respiratory epithelial cells and airway macrophages
[1–3]. Airway colonization and infection occur with few
pathogens such as Pseudomonas aeruginosa, Staphylococcus
aureus, or both, even in infants at a very young age. Bacterial
shedding of immunostimulatory pathogen-associated molecular
patterns (PAMPs), such as cell-wall components, lipopolysaccha-
ride (LPS), flagella and DNA, activate a brisk proinflammatory
response. Due to bacterial adaptation and selection of mutants, the
PMN response is not capable to clear bacteria from theCF airwaysby Elsevier B.V. All rights reserved.
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by P. aeruginosa release proteases that disable any neighbouring
viable neutrophils [5].
Initially considered as inert cellular debris released from
activated platelets in human plasma [6], microparticles (MPs)
have emerged as a new concept of biomarker and biovector.
MPs are small vesicles released from cells after activation by
chemical (apoptotic, proinflammatory, prothombotic) or phys-
ical (shear stress) stimuli [7], they are surrounded by a lipid
bilayer composed mainly of phospholipids, cholesterol and
membrane-associated proteins, and are enriched with intracel-
lular components such as proteins for signal transduction,
mRNA, and miRNA [8]. MPs are heterogeneous in size (0.1–
1 μm) and their composition depends on both cell origin and
stimulation implicated during their generation. Thus all types
of cells can theoretically release MPs at each stage of their life
cycle, but the intracellular mechanism involved in MP
formation are not completely elucidated [7].
MPs presence has also been documented in the bronchoal-
veolar lavage fluid (BALF), where MPs derived from platelets
were found in pulmonary air–liquid interfaces in sedated pigs
[9]. Bastarache and colleagues [10] described procoagulant
MPs in BALF from acute respiratory distress (ARDS) patients,
contributing with tissue factor to intra-alveolar fibrin formation,
a critical pathogenic feature of acute lung injury (ALI). Further
studies have demonstrated the MP role in the pathogenesis of
different aspects of ALI/ARDS (for review see [11]).
In a previous study, our group for the first time was able to
isolateMPs from the sputum of CF patients [12], finding thatMPs
in CF sputum are mainly derived from PMNs. Here, we have
analyzed the pro-inflammatory potential of MPs isolated from the
sputum of CF patients in the mouse lung, and compared their
effects with those elicited by the administration of MPs isolated
from the sputum of Primary Ciliary Dyskinesia (PCD) patients, a
disease characterized by opportunistic pathogen infection of the
upper and lower respiratory tract and neutrophilic inflammation
[13].
2. Materials and methods
2.1. Patients
The study was approved by, and performed in accordance
with, the ethical standards of institutional review boards of
University of Foggia and Hospital of Cerignola on human
experimentation. Written informed consent was obtained from
each subject.
We enrolled 6 CF patients who consecutively had been
admitted at the CF Center of the Hospital of Cerignola “G.
Tatarella” for parenteral (intravenous) antibiotic therapy during
acute respiratory exacerbation, and 4 stable CF patients. Exacer-
bation was defined as a deterioration in symptoms perceived by the
patient and included an increase in cough, sputum production,
dyspnoea, decline in forced expiratory volume in 1 s (FEV1)
compared with previous best, weight loss and fever [14]. Each
patient was given a clinical score obtained from the sum of
the individual parameters (0 = no symptom; 1 = moderate; 2 =severe). Serum C-reactive protein (CRP) was assessed as a marker
of active inflammation [15]. CF patients were compared with 4
PCD patients.
Bacterial species in sputum specimens were identified
accordingly to the North-American guidelines [16]. Sputum
samples were directly spread-out in selective media, such
as MacConkey agar for P. aeruginosa, mannitol salt agar
for S. aureus, and BCSA for Burkholderia cepacia complex, and
incubated at 36 ± 1 °C for a period of 18–72 h. Colonies were
quantified and identified by classical (manual) phenotypical tests.
2.2. MP isolation from sputum
MPs were isolated as previously described by our group
[12]. Briefly, spontaneous sputum was solubilized by treatment
with Sputasol® (SR 0233A, Oxoid Ltd, Hampshire, UK), and
then incubated in a water bath at 37 °C for 15 min until visible
homogeneous. Processed sputum was centrifuged at 37 ×g for
3 min; the supernatant was centrifuged at 253 ×g for 10 min
and then re-centrifuged at 253 ×g for 20 min to remove the
cells and large debris, respectively. MP-containing supernatant
was centrifuged at 14,000 ×g for 45 min to pellet MPs. MP
pellet was subjected to two series of centrifugations at
14,000 ×g for 45 min. Finally, MP pellet was re-suspended in
500 μL of 0.9% saline salt solution and stored at +4 °C until
total counting and usage.
To determine MP number, 10 μL of Flowcount beads
(Beckman Coulter, Ireland) was added to each sample and
analyzed in a flow cytometer (Beckman Coulter coulter epics
XL-MCL). Sample analysis was stopped after the count of
10,000 events.
2.3. Isolation of CD66b-positive MPs
Positive selection of CD66b-positive MPs by EasySep
(Human whole Blood CD66b positive selection kit; StemCell
Technologies Inc., Vancouver, Canada) was done accordingly to
the manufacturer's instructions. Briefly, recovered total sputum
MPs, re-suspended in the appropriate medium, were incubated
with the EasySep CD66 positive selection cocktail, a tetrameric
antibody complex which recognizes CD66 and dextran, the
successive step being the addition of dextran-coated magnetic
nanoparticles. Magnetically labelled target cells were then
separated from unlabeled unwanted cells using the EasySep
magnet by pouring the unlabelled cells off.
2.4. Isolation of blood MPs
Peripheral blood (20 mL) from healthy donors and CF
patients was collected in EDTA-treated tubes from a peripheral
vein using a 21-gauge needle to minimize platelet activation
and was processed for assay within 2 h [17]. After a 20 min
centrifugation (270 ×g), platelet-rich plasma (PRP) was separated
from whole blood. PRP was then centrifuged for 20 min
(1500 ×g) to obtain platelet-free plasma (PFP). PFP (MP
containing) was spun down at 14,000 ×g for 45 min to pellet
MPs. The MP pellet was then centrifuged twice at 14,000 ×g for
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0.9% saline salt solution and stored at 4 °C, as previously
described [12]. An equal volume of sample and Flowcount beads
(Beckman Coulter, Ireland) were added and samples were
analyzed in a flow cytometer 500 MPL System (Beckman
Coulter coulter epics XL-MCL).
2.5. Binding of LPS to blood MPs
MPs (1 × 106), isolated from blood, were re-suspended in
500 μL of saline and incubated for 2 h with 10 μg/mL LPS from
P. aeruginosa (serotype 10, Sigma-Aldrich). After incubation,
MPs were washed three times with 0.9% saline salt solution to
remove unbound LPS and then re-suspended in saline. The levels
of endotoxin were assessed in MP preparations with the Limulus
amebocyte lysate kit.
2.6. Isolation and LPS stimulation of PMNs
Human PMNs were isolated according to standard tech-
niques from heparin anticoagulated venous blood from healthy
consenting adults. PMNs were isolated using dextran sedi-
mentation and Hypaque-Ficoll (Amersham Biosciences, Europe
GmbH, Freiburg, Germany) density-gradient separation, followed
by hypotonic lysis of erythrocytes as previously described [18].
Cells were suspended in serum-free RPMI 1640 without phenol
red. PMN viability, as assessed by trypan blue exclusion assay,
was≥90% prior to experimental use. PMNs (1 × 106) were then
treated in the absence or in the presence of 10 μg/mL of LPS
for 24 h in culture medium (RPMI 1640 supplemented with
10% of heat inactivated fetal calf serum, 10 mM HEPES,
2 mM L-glutamine, 100 U/mL penicillin and 100 μg/mL strep-
tomycin). After the incubation the cells were centrifuged at
500 ×g for 5 min at room temperature. The supernatants was
collected and centrifuged at 1500 ×g to pellet cellular debris. The
supernatant containing MPs was centrifuged at 14,000 ×g for
45 min to pellet LPS-stimulated PMN-derived MPs. PMN MPs
were washed three times and resuspended in 0.9% saline salt
solution, then the levels of endotoxin were assessed in MP
preparations with the Limulus amebocyte lysate kit.
2.7. Limulus amebocyte lysate assay
The presence of bacterial endotoxin in MP preparations
was quantified with the limulus amebocyte lysate assay, the
kinetic-QCL kit (Lonza, Walkersville, MD), according to the
manufacturer's instructions. A standard curve was used to
determine the concentration of endotoxin in the samples and
expressed as endotoxin unit per milliliter (EU/mL).
2.8. Animal model of acute lung inflammation
All animal procedures were approved and controlled by the
Institutional Review Board of University of Foggia and by the
Italian Ministry of Health and carried out according to the
guidelines of the Italian law of protection of animal life and to
the Helsinki Declaration.The experiments were performed using 6–8 weeks old
male Swiss mice (Charles River laboratories, Calco, Italy)
with a body weight of 23–27 g. They were housed and
handled according to institutional guidelines which comply
with Italian legislation and were given food and water ad
libitum.
Lung inflammation was provoked by intratracheal adminis-
tration of LPS or MPs. Mice were anesthetized intraperitoneally
with 2,2,2-tribromoethanol (Avertin, Sigma-Aldrich, prepared
2.5% wt/vol in PBS and used 0.015 mL/g body weight) and
restrained in a vertical position with their necks tilted back so as
to result in an accessible position of the trachea for intubation.
Using two pairs of tweezers, the mouth was carefully opened and
the tongue was gently pulled out. Then each animal received in
total 150 μL, three times 50 μL-bolus of LPS (20 μg), saline
(control mice) or different number of MPs in saline (25, 50, and
100 × 106) introduced into the trachea, using a 22-gauge
intravascular cannula sleeve, needle removed (25 mm, 0.9 mm
out diameter, 0.6 mm internal diameter; Baxter, Germany). To
avoid false intubation into esophagus the trachea was illuminated
via an otoscope held perpendicularly to the animal's throat,
producing a well-illuminated trachea through dispersed light. At
24 h after LPS or MP treatment, the animals were killed by
sodium penthotal hyperanaesthesia and their chests opened to
expose lungs and heart.
To obtain bronchoalveolar lavage fluid (BALF) specimen, the
trachea was exposed through a midline incision and cannulated
with a sterile 23-gauge needle. BAL was performed by instilling
0.9% NaCl in two separate 1 mL aliquots. The fluid was
recovered by gentle suction and placed on ice for immediate
processing. An aliquot of the BALF was processed immediately
for total and differential cell counts. Total cell counts were
performed with a hemocytometer, whereas differential cell
counts were performed on cytospin preparations stained with
May-Grunwald Giemsa. The cytological evaluation was
performed on the basis of morphological differences between
macrophages and neutrophils. In particular, macrophages
were identified as they are 13–15 μm in diameter, with an
ovoid or kidney-shaped nucleus and containing azurophilic
granules, while neutrophils are 10 μm in diameter, have a
nucleus with three to five lobes connected by threads of
chromatin and cytoplasm containing very fine granules which
give a light-gray aspect to cytoplasm.
After lavage lung was removed and fixed in formaldehyde.
The fixed samples were embedded in paraffin, thin-sectioned,
mounted on glass microscope slides using standard histopatho-
logical techniques and visualized to Nikon Eclipse E1000 M
microscopy.2.9. Statistical analysis
Data are shown as mean ± SEM. Statistical significance
was studied by the non-parametrical Mann–Whitney test. All
data were analyzed using Prism 4 (GraphPad Software, Inc.,
La Jolla, CA). P values of less than 0.05 were considered
significant.
Table 1
Baseline characteristics of patients.
Stable CF Acute CF PCD
N 4 6 4
Age (years) 26.2 ± 6.4 22.0 ± 2.5 25.7 ± 6.1
Sex ratio (male:female) 2:2 1 1:3
F508del homozygous 1 4 /
F508del heterozygous 1 1 /
Other mutations 1 1 /
FEV1 (%) 57.1 ± 9.9 66.8 ± 5.5 82.9 ± 10.3
CRP (mg/dl) 0.3 ± 0.3 2.2 ± 1.2 0.13 ± 003
Clinical score 2.5 ± 0.2 7.2 ± 0.2* /
Source of infection
Pseudomonas aeruginosa 3 2 1
Staphylococcus aureus 1 1 1
Burkholderia cepacia complex 0 3 0
Negative 0 0 2
Data are shown as mean ± SEM. FEV1, forced expiratory volume in 1 s as %
predicted; CRP. C reactive protein. In 1 stable CF patient analysis of CFTR
mutations is missing. *Acute vs. stable CF: P b 0.05.
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3.1. Study patients
Characteristics of patient are summarized in Table 1. CF
patients had more expiratory airflow obstruction, as measuredFig. 1. Histopathology of mouse lung. Swiss mice were administered with saline (a),
patients, or from a patient with PCD (g). In mice injected either with LPS or acute CF M
shown in b and d panels respectively. c and e panels show the peribronchial/perivascular
MPs from stable CF and PCD generated a more diffuse parenchymal infiltration and thby the FEV1% predicted, although not significantly different
from PCD patients, and were more likely to be colonized with
P. aeruginosa, S. aureus, and B. cepacia complex. The acute
and stable groups of CF patients were well differentiated on the
basis of clinical score (Table 1). While all CF patients were
positive for sputum bacterial species, two out of four PCD
patients were negative for bacteria in their sputum.3.2. In vivo inflammatory effect of sputum MPs
MPs were isolated from sputum specimens of CF and PCD
patients and counted. For histopathological analysis, 50 × 106
MPs were injected to the lung of Swiss mice via intratracheal
administration. Fig. 1 shows the histopathology of lung sections in
negative controls (injected with saline), LPS-injected (as a positive
control), and injected with CF or PCD MPs at 24 h post-
administration. As expected, the lungs of control mice (Fig. 1a)
were spared by the infiltration of inflammatory cells, while
lungs of LPS-infected mice (Fig. 1b and c) displayed a patchy
infiltration of parechyma by inflammatory cells, with peribronchial
and perivascular infiltrates (Fig. 1c). MPs obtained from a CF
patient in acute conditions evoked a patchy cellular infiltrate
(Fig. 1d) and peribronchial/perivascular infiltrates (Fig. 1e),
similar to that obtained with LPS, whereas the inflammatoryLPS from P. aeruginosa (b, c), 50 × 106 MPs from acute (d, e) or stable (f) CF
Ps, the lung inflammation was patchy and a single field from LPS and from CF is
infiltration in mice administeredwith LPS and acute CFMPs respectively (arrows).
us only a single field for each condition is shown. Original magnification: 20×.
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patients were injected (Fig. 1f). MPs obtained from a PCD
patient caused as well a diffuse infiltration of inflammatory
cells in the parenchyma with predominant peribronchial
infiltrates (Fig. 1g). Higher magnification showed a massive
neutrophil infiltrate in lungs administered with MPs obtained
from a CF in stable condition (Fig. 2a), a similar picture being
obtained with the lung sections of mice dosed with MPs
obtained from a CF patient in acute condition (not shown). The
lung of mice injected with MPs obtained from a PCD patient
showed instead a higher number of infiltrating macrophages
(Fig. 2b).
We analyzed a dose response relationship by total and
differential counts of inflammatory cells in BALF. LPS
administration determined a significant increase of total cellular
count as compared with control mice (Fig. 3A). MPs obtained
from CF patients in acute state were inflammatory as well, with
a peak of total cell counts obtained with 100 × 106 MPs
injected. Interestingly, MPs obtained from stable CF patients
were not as pro-inflammatory as those obtained from acute CF
patients (Fig. 3B), confirming the histopathology findings. MPsFig. 2. Histological analysis of the inflammatory infiltrate. Lung slides obtained
from mice injected with MPs obtained from either a CF patient in stable state
(a) or a PCD patient (b) were analyzed at higher magnification (60×). Panels are
representative of three images obtained from each treated mouse. Black arrows
point in a) and b) to PMNs and macrophages, respectively.obtained from PCD patients determined inflammatory levels
similar to those elicited by acute CF MPs (Fig. 3B).
The analysis of differential cell counts revealed that whereas
control mice had only macrophages (MO) in their BALF, LPS
administration determined an increase in neutrophil numbers
(Fig. 3C). The injection of 25 × 106 MPs obtained from acute
CF patients did not induce a significant increase in neutrophil
number, whereas 50 and 100 × 106 determined a higher number
of neutrophils (P = 0.021 and P = 0.043 for PMN CF50 vs.
PMN control and PMN CF100 vs PMN control, respectively).
Correspondingly, the administration of 50 and 100 × 106 CF
MPs caused a significant decrease in the number of macrophages
in comparison to saline-injected mice (P b 0.0001 for both MO
CF50 vs. MO control and MO CF100 vs. MO control). When
counts from mice injected with MPs from acute and stable CF
patients were compared, no differences were found (Fig. 3D).
PCD MPs behaved differently, since the most of inflammatory
cells were macrophages.3.3. LPS-like activity of sputum MPs
Since sputum MPs exhibit a high pro-inflammatory potential
when administered in vivo in the mouse lung, we analyzed the
LPS-like activity of such MPs isolated from sputum and blood
from CF and PCD patients. Limulus test revealed that CF
sputum MPs contained 3.1 ± 0.07 EU/mL, whereas CF blood
MPs contained negligible expression (Table 2). LPS-like
activity of sputum MPs did not differ among those derived
from patients infected byB. cepacia (3.28 ± 0.09 EU/mL; n = 3),
P. aeruginosa (2.96 ± 0.13 EU/mL; n = 2), or S. aureus
(2.90 EU/mL; n = 1). MPs isolated from PCD sputum contained
as well high levels of LPS-like activity (3.7 ± 0.03 EU/mL). In
our previous study [12], we have shown that most of CF sputum
MPs were of neutrophil origin. Thereby, CF sputum MPs were
enriched for CD66 by a positive selection immunomagnetic
procedure and analyzed for LPS-like activity. In this assay, we
considered only CF patients with an acute exacerbation. The
results were compatible for Limulus activity mainly harboured by
theseMPs, which showed 3.5 ± 0.03 EU/mL. These data strongly
indicate that LPS is not a soluble contaminant of the MP
preparation but that it is intimely associated with the MPs
themeselves and is enriched in MP-derived neutrophils.3.4. Binding of LPS to MPs
In order to determine whether MPs bind LPS, we performed
binding experiments by incubating LPS with MPs freshly
isolated from blood and with circulating PMNs, in both cases
blood was drawn from human healthy donors. MPs isolated from
blood stimulated with LPS showed high levels of LPS-like
activity as compared withMPs obtained from unstimulated blood
(Table 3). Finally, we next adressed the question whether also
MPs obtained from blood PMNs stimulated with LPS carry
LPS-like activity. Indeed this was the case, since a high LPS-like
activity was found on these MPs (Table 3).
Fig. 3. Total number and differential cell counts of inflammatory cells in BALF. Mice were administered with saline (control) LPS, MPs from acute or stable
CF patients, or MPs from PCD patients. Panels A) and B) refer to total number of inflammatory cells, while panels C) and D) to the differential counts.
A) Dose-dependence of lung inflammation as determined by different doses of MPs (25, 50, 100 × 106) obtained from acute CF patients (n = 5–8 mice per group).
*P b 0.05 for LPS and MPs vs. control. B) Comparison between acute and stable CF patients and PCD patients (n = 4–7 mice per group). In A) and B) each mouse
was dosed with a MP preparation from a single patient. *P b 0.05 for stable CF vs. acute CF. C) Dose-dependence of lung inflammation as determined by different
doses of MPs (25, 50, 100 × 106) obtained from acute CF patients. MO and PMN numbers are shown as the percentage of total cell counts. (n = 5–8 mice per group).
** P b 0.005 for PMN FC50 and FC100 vs. control; ***P b 0.001 for MO FC50 and FC100 vs. control. D) Comparison between acute and stable CF patients and
PCD patients (n = 4–7 mice per group). In C) and D) each mouse was dosed with a MP preparation from a single patient.
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In this paper we have demonstrated that MPs obtained from
CF sputum are pro-inflammatory when injected into the murine
lung, determine a strong neutrophil infliltrate in the parenchyma
and at the perivascular/peribronchial level, and that, among the
possible mediators involved, LPS has a putative role. To the best
of our knowledge, this is the first study reporting lung injury
following intratracheal administratrion of MPs, whereas other
studies showed the induction of acute lung injury upon
intravenous injection of endothelial-derived MPs [19,20].Table 2
LPS-like activity associated with MPs.
Source of MPs Number of MPs used in the
assay (×106)
LPS-like activity
(EU/mL)
CF sputum 14.5 ± 7.8 3.1 ± 0.07
CF blood 5.2 ± 0.47 0
CF sputum CD66b+ PMN 0.077 ± 0.017 3.5 ± 0.03
PCD sputum 20.7 ± 0.39 3.7 ± 0.03
LPS-like activity was evaluated in MPs isolated from CF sputum (n = 6), blood
(n = 6), sputum CD66b+ PMN (n = 5), and PCD sputum (n = 4). Data are
shown as mean ± SEM.Although the CF lung disease is chronic, the clinical history is
punctuated by intermittent episodes of acute worsening of
symptoms, more commonly referred to as pulmonary exacerba-
tions [14]. There are a number of potential causes of an
exacerbation that have been suggested [14], and these include
acute events as well as further progression of the chronic infection
and inflammation in the airways [21,22]. In this study we
demostrated that MPs are able to determine an acute inflammatory
response in a mouse model. The histopathological analysis showed
that the administration of CF sputumMPs in mouse lung induced a
strong infiltration of parenchyma by inflammatory cells, with MPsTable 3
Binding of LPS to MPs.
Source of MPs LPS-like activity (EU/mL)
Blood-derived MPs 0.18 ± 0.11
Blood-derived MPs after incubation with LPS 1.99 ± 0.07
LPS-stimulated neutrophil-derived MPs 1.72 ± 0.07
LPS-like activity was evaluated in MPs (1 × 106) obtained from blood of
healthy donors before and after LPS incubation (n = 6), and in MPs (1 × 106)
obtained from neutrophils stimulated with LPS (n = 5). Data are shown as
mean ± SEM.
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inflammatory cells. The histology and the analysis of differential
cell counts of BALF demonstrated that CF MPs elicited a
neutrophil-dominated inflammation, whereas PCD MPs deter-
mined a macrophage-enriched inflammatory response. These
results likely reflect the different spectrum of bioactive substance,
membrane-anchored receptors, adhesion molecules, cytokine,
chemokine, enzyme, growth factors, signalin proteins mRNA and
microRNA present in MPs [23]. PCD is characterized by a
neutrophil-dominant inflammation in upper and lower airways
although in lesser degree than CF [13], and PCD airways are
colonized later by P. aeruginosa and not so frequently as in CF
[24], as also shown by clinical data presented in Table 1. This
suggests either that MPs are not involved in PCD airway
inflammation or that PCDMPs are endowed with signals different
from CF MPs. Nevertheless, LPS-like activity was found also in
PCD MPs, suggesting that it is only one of the signals transported
by MPs.
Although antigens found on the surface ofMPs and the cargo of
MPs resemble those on the their parental cells, MPs represent more
than just a miniature version of the specific cell of origin, as certain
MP components are enriched compared to their parental cell and as
the composition and the function of MPs not only depends on the
cellular origin but also on the stimuli responsible for the MP
formation and the microenviroment of the parental cell [23]. The
stimulus that triggers MP formation regulates the selective sorting
of specific constituents that determine the composition ofMPs and,
consequently, the biological information that they transfer.
MP-associated intercellular communication can take place through
different pathways. They can (i) directly interact with the ligands
present on the surface of target cells and activate cascade signaling,
and (ii) transfer proteins, mRNA, miRNA, and bioactive lipids by
interacting with target cells by either by fusion or internalization.
Through this latter mechanism, target cells can acquire new surface
antigens and therefore new biological properties and activities [25].
In vitro studies have shown that LPS in combination with
cytokines increases endothelial cell production of MPs [26]
that was interpreted as playing a potential role in the
mechanisms by which complement increases acute lung injury
[27]. In CF, it has been recognized that P. aeruginosa live
anaerobically in the mucus layer of the lung and is rarely found
in contact with epithelial cells [28]. Like other Gram-negative
bacteria, P. aeruginosa release spheres of outer membrane that
are enriched in LPS, glycerophospholipids, and outer mem-
brane proteis, and are internalized by human lung cells [29].
These vesicles could be the vehicle of LPS which is known to
be shedded by bacteria in the CF airways [30]. Moreover,
P. aeruginosa vesicles induce a significant IL-8 response from
cultured lung cells [31]. Thus, the pro-inflammatory effects of
LPS shedded from live bacteria might be considered in the
context of pathophysiology of the CF airway disease.
To explore one of possible mechanism of the MP-inducted
lung inflammation, we tested the presence of LPS-like activity on
blood MPs, CF sputum MPs and CF sputum MPs enriched for
CD66b, the MPs most represented in CF sputum according with
our previous study [12]. We found a higher LPS-like activity
demonstrating that LPS is intimely associated with the MPsthemeselves. LPS could be present on sputum MPs for two
different reason; one is due to the binding of free LPS present in
lung district because the incubation of MPs with LPS makes the
MPs enriched with LPS-like activity. The second reason is that
LPS is able to induce neutrophil apoptosis and theMPs generated
in this way presented LPS on MPs elicited by this process.
Interestingly, LPS-like activity was not present in MPs prepared
from CF blood, indicating that, although high levels of serum
LPS has been demonstrated in stable CF patients previously
hospitalized for an acute exacerbation [32], either LPS does not
associate with serum MPs or the association is transient.
However, the first hypothesis is unlikely since LPS-like activity
was present in blood MPs after incubation with LPS (Table 3).
We acknowledge that this study contains a number of
limitations. First, the inflammatory response in vivo was studied
at 24 h post-injection, thus we do not know if CF MPs may
sustain lung inflammation for longer times, as we have previously
shown for LPS [33]. Second, we have not addressed other
mechanism(s) in MP-induced inflammatory lung response apart
from LPS. For example, platelet-activating factor enriched MPs
arised from PMN stimulated with LPS were able to activate
platelets [34], while other studies have shown that PMNMPs can
activate endothelial cells to generate IL-6 and vascular inflam-
mation [35–37].
In summary, we have demonstrated thatMPs isolated fromCF
sputum display a high pro-inflammatory effect in vivo in the
mouse lung and that these MPs presented high LPS-like activity.
These data suggest that the pro-inflammatory potential of
neutrophil-derived MPs in the CF airways may be subsequent
to the binding of shedded LPS. A better understanding of
formation, function and relevance of MPs may give rise to new
promising therapeutic strategies to modulate inflammation in CF
and other lung diseases.Acknowledgments
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